Skip to main content
Acute Medicine & Surgery logoLink to Acute Medicine & Surgery
. 2014 Dec 11;2(3):163–168. doi: 10.1002/ams2.97

Oxidative stress and heart rate variability in patients with vertigo

Keiichiro Ohara 1,, Yoshiaki Inoue 1, Yuka Sumi 1, Miki Morikawa 1, Shigeru Matsuda 1, Ken Okamoto 1, Hiroshi Tanaka 1
PMCID: PMC5667254  PMID: 29123715

Abstract

Aims

Peripheral vertigo has been reported to result from oxidative stress or autonomic nervous dysfunction. Recently, heart rate variability has been used to evaluate autonomic nervous activity. Parasympathetic nervous dysfunction is associated with peripheral vertigo; however, the relationships between vertigo, oxidative stress, and autonomic nervous activity have not been investigated. The aim of this study was to elucidate the changes in oxidative stress and autonomic nervous activity in vertigo patients compared with healthy volunteers.

Methods

Oxidative stress was assessed by evaluating biological antioxidant potential and reactive oxygen metabolites, and heart rate variability was measured to evaluate autonomic nervous activity. Thirty‐four patients who complained of peripheral vertigo and were treated in our emergency department between January and August 2011 were enrolled in study 1. Oxidative stress and heart rate variability were measured and compared with those of healthy volunteers (n = 23). In study 2, oxidative stress in 18 vertigo patients and heart rate variability in 41 vertigo patients were measured between January and August 2012 before and after conventional treatment of vertigo to evaluate the effect of the treatment on oxidative stress and autonomic nervous activity.

Results

Reactive oxygen metabolites were higher in vertigo patients than in healthy volunteers. Parasympathetic nervous activity was lower and the sympathetic/parasympathetic nervous activity ratio (autonomic nervous activity ratio) was higher in vertigo patients than in healthy volunteers. After treatment of vertigo, reactive oxygen metabolites decreased significantly and the autonomic nervous activity ratio became similar to that observed in healthy volunteers.

Conclusions

Bedside monitoring of oxidative stress and heart rate variability may be useful for the diagnosis of vertigo and evaluation of the effect of treatment.

Keywords: Autonomic nervous activity, heart rate variability, oxidative stress, vertigo

Background

Patients who complain of vertigo are often transported to an emergency department (ED). Multiple factors induce vertigo, because the sense of balance requires proper functioning of multiple body parts including the inner ears, eyes, muscles, skeleton, and nervous system. In the USA, the common causes of vertigo have been reported as aural (32.9%), cardiological (21.1%), neurological (11.2%), cerebrovascular (4%), and others (34.8%) including injury, psychiatric disease, or infectious disease.1

The pathophysiological mechanism of vertigo has been studied and physiological stress appears to play an important role. House et al. reported that Meniere's disease was not caused by psychological disorders but by biological stress; patients with Meniere's disease are in stressful situations.2 Most of the previous studies evaluating physiological stress used patient interviews because physiological stress was difficult to measure quantitatively. Recently, methods for quantitative evaluation of physiological stress have become available in the clinical setting. In particular, oxidative stress (OS) and autonomic nervous activity (ANA) are major targets for clinical evaluations of physiological stress. For example, protein carbonyl levels were previously used as an indicator of protein oxidation. It was revealed that protein carbonyl was higher in patients with Meniere's disease than in controls.3 These findings suggested that antioxidant therapy may be useful for patients with Meniere's disease.4, 5 It has been reported that ANA could be evaluated by assessing heart rate variability (HRV).6 Heart rate variability can reflect the dynamic interplay between ongoing perturbations in circulatory function and the compensatory responses of short‐term cardiovascular control systems. Analysis of HRV7, 8, 9 includes low‐frequency (LF) fluctuations, which reflect both parasympathetic and sympathetic activity, and high‐frequency (HF) fluctuations, which reflect parasympathetic activity. These findings have been used for the evaluation of ANA in vertigo patients. Although some reports have described the relationship between vertigo and physiological stress,2, 3, 4 to the best of our knowledge, no study has examined OS and ANA in vertigo patients. In particular, changes in physiological stress have not been compared before and after the treatment of vertigo. In this study, OS and HRV were evaluated in vertigo patients compared with healthy volunteers (HVs) and the effect of treatment was evaluated.

Patients and Methods

Overall protocol

This study was approved by the Institutional Review Board of Juntendo University (Urayasu City, Japan) (approval number 23–32) and informed consent was obtained from each patient or a close relative. Subjects were recruited from patients transferred by ambulance to the ED of Juntendo University Urayasu Hospital. The exclusion criteria included age <15 years, vertigo due to central nervous system disease, or other injuries.

Measurements

For each patient, whole blood samples (10 mL) were collected from a peripheral vein into heparin‐coated tubes within 30 min of arrival to the ED to assess OS by measuring biological antioxidant potential (BAP) and reactive oxygen metabolites (dROM). Blood samples were centrifuged for 5 min at 22560G, and the collected serum samples were divided into two tubes of at least 2 mL each; these samples were rapidly frozen at −80°C. These samples were defrosted within 72 h and BAP and dROM were measured using Free Radical Analytical System 4 (Health and Diagnostics, Parma, Italy). Biological antioxidant potential reflected the blood level of antioxidant substances. The BAP test uses a colored solution containing ferric (Fe3+) ions bound to a special chromogenic substrate that changes color when the Fe3+ ions are reduced to ferrous ions (Fe2+). Then 10 μL of the serum sample was added to the cuvette. After incubating for 5 min at 37°C, absorbance at 505 nm was recorded. The dROM test reflected the blood level of reactive oxygen metabolites, particularly that of hydroperoxides, which are markers and amplifiers of free radical‐induced oxidative damage. In this test, the ROM level is proportional to the intensity of red coloration. In brief, 20 μL blood and 1 mL buffered solution were mixed in a cuvette, and 10 μL chromogenic substrate was added to the cuvette. After mixing and centrifugation for 60 s, the cuvette was incubated in a thermostatic block for 5 min at 37°C. Thereafter, absorbance at 505 nm was recorded. The results were expressed as U.CARR.

Heart rate variability was assessed using a sphygmograph (TAS9 Pulse Analyzer Plus; YKC Corp., Tokyo, Japan) attached to the left forefinger while the patient lay silently on a bed in the supine position with their eyes closed. It was recorded for 2.5 min and the frequency domain information was analyzed automatically with a fast Fourier transform. The technical details of HRV analysis have been presented in detail previously.8, 9, 10 In brief, the power spectral components of the R–R interval between 0.04–0.15 Hz were considered LF components and those between 0.15–0.40 Hz were considered HF components. The heart rate data was sampled immediately after each heart beat and was transferred to a personal computer and analyzed with supplied software. The heart rate values were averaged, and the LF and HF power values were calculated by integrating each frequency band every 2.5 min; these measurements were then subjected to further analysis.10 Patients with arrhythmias were excluded from HRV analysis, because HRV could not be measured correctly with an irregular heart rhythm.

Study protocol and evaluation

Using these OS (BAP, dROM) and HRV measurements, we established two study protocols. In the first (study 1), OS and HRV were compared between vertigo patients treated at our ED between January to August 2011 and HVs (n = 23). In the second (study 2), OS and HRV in vertigo patients were compared before and after conventional treatment of vertigo. This treatment included a 2‐h infusion of Sordem 3A (200 mL; Ohtsuka, Tokyo, Japan) mixed with adenosine triphosphate (ATP) disodium hydrate (40 mg) and 8.4% sodium bicarbonate (20 mL). If the patient complained of nausea, 10 mg metoclopramide was injected through the intravenous line. Whole blood samples (10 mL) were collected immediately after visiting the ED for the “before treatment” data and then collected immediately after the 2‐h infusion for the “after treatment” data. Patients included in the second study were treated in our ED between January and August 2012.

Statistics

Data are expressed as mean ± standard deviation (SD). Welch's t‐test was used for comparisons of groups in study 1, and the paired t‐test was used in study 2. Statistical analyses were carried out using GraphPad Prism 5 software (GraphPad Software, La Jolla, CA, USA). P‐values <0.05 were considered statistically significant.

Results

Patient background

The patients selected for studies 1 and 2 are shown in Figure 1. In study 1, BAP and dROM were measured in 34 patients (age, 64 ± 15 years; 12 males and 22 females), and HRV in 24 patients (age, 56 ± 17 years; 9 males and 15 females). Twenty‐three HVs (age, 36 ± 11 years; 15 males and 8 females) were included in this study as a control group. Ten patients were excluded because of arrhythmia. In study 2, HRV was measured in 41 patients (age, 59 ± 14 years; 15 males and 26 females) before and after the treatment of vertigo, whereas BAP and dROM were evaluated in 18 patients (age, 65 ± 15 years; 6 males and 12 females). Twenty‐three patients were excluded because they did not give consent (Fig. 1).

Figure 1.

figure

Patient selection in two studies of oxidative stress and heart rate variability (HRV) in vertigo patients. A: In study 1, biological antioxidant potential (BAP), reactive oxygen metabolites (dROM) (n = 34), and HRV (n = 24) were compared between vertigo patients and healthy volunteers (n = 23). B: In study 2, BAP, dROM (n = 18), and HRV (n = 41) were measured in vertigo patients before and after treatment.

Oxidative stress in vertigo patients

We measured BAP, dROM, and the BAP/dROM ratio in vertigo patients compared with HVs (Fig. 2). The BAP/dROM ratio was evaluated to investigate the balance of OS. Reactive oxygen metabolites were significantly higher in vertigo patients (Pt) than in HVs (HVs, 295 ± 51 U.CARR; Pt, 337 ± 60 U.CARR; Fig. 2B, P < 0.01). There was no significant difference in BAP (HVs, 2,183 ± 207 μM; Pt, 2,207 ± 429 μM; Fig. 2A) or the BAP/dROM ratio (HVs, 7.74 ± 2.15; Pt, 6.79 ± 1.91; Fig. 2C). These results indicate that superoxide and oxygen metabolites were higher in vertigo patients than in HVs.

Figure 2.

figure

Comparison of oxidative stress in vertigo patients and healthy volunteers in terms of biological antioxidant potential (BAP) (A), reactive oxygen metabolites (dROM) (B), and BAP/dROM ratio (C). Open circles show healthy volunteers (HVs) (n = 23), and closed circles show vertigo patients (n = 34). **P < 0.01, Welch's t‐test.

Autonomic nervous activity in vertigo patients

Sympathetic nervous activity (LF/HF), parasympathetic nervous activity (HF), and the sympathetic/parasympathetic nervous activity ratio, which is reflective of ANA balance (LF/HF2, defined as the ANA ratio), were assessed (Fig. 3). All data were log transformed and compared with the values of HVs. There was no significant difference in sympathetic nervous activity between HVs and vertigo patients (HVs, 1.02 ± 0.23; Pt, 1.14 ± 0.30; Fig. 3A). However, parasympathetic nervous activity in vertigo patients was significantly suppressed (HVs, 5.27 ± 1.00; Pt, 4.13 ± 2.34; Fig. 3B, P < 0.05) and the ANA ratio was significantly elevated compared with HVs (HVs, 0.20 ± 0.08; Pt, 0.47 ± 0.51; Fig. 3C, P < 0.05). These results suggest that ANA balance was disturbed in vertigo patients.

Figure 3.

figure

Comparison of autonomic nervous activity in vertigo patients and healthy volunteers. A: Sympathetic nervous activity. B: Parasympathetic nervous activity. C: Autonomic nervous activity ratio expressed as the sympathetic/parasympathetic nervous activity ratio. Open circles show healthy volunteers (HVs) (n = 23), closed circles show vertigo patients (n = 24). *P < 0.05, Welch's t‐test. HF, high frequency; LF, low frequency; LN, logarithmus naturalis.

Effect of treatment on OS in vertigo patients

The changes in BAP, dROM, and the BAP/dROM ratio before and after the 2‐h treatment of vertigo are shown in Figure 4. Reactive oxygen metabolites were significantly reduced after treatment (before, 349 ± 60 U.CARR; after, 331 ± 60 U.CARR; Fig. 4B, P < 0.01). However, no significant difference was observed in BAP (before, 1,985 ± 325 μM; after, 1,941 ± 278 μM; Fig. 4A) or the BAP/dROM ratio (before, 5.88 ± 1.47; after, 6.07 ± 1.44; Fig. 4C). The symptoms improved in 16 patients after treatment, and 2 patients were admitted to our hospital for observation.

Figure 4.

figure

Effect of treatment of vertigo on oxidative stress. biological antioxidant potential (BAP) (A), reactive oxygen metabolites (dROM) (B), and BAP/dROM ratio (C) before (left) and after (right) treatment in vertigo patients (n = 18). Gray area indicates mean ± SD of healthy volunteers (n = 23). **P < 0.01, paired t‐test.

Effect of treatment on ANA in vertigo patients

Figure 5 shows ANA, expressed as HRV, in 41 vertigo patients before and after treatment. There was no change in sympathetic nervous activity (before, 1.21 ± 0.42; after, 1.14 ± 0.32; Fig. 5A) or parasympathetic nervous activity (before, 4.08 ± 1.96; after, 4.07 ± 1.11; Fig. 5B) after treatment. The ANA ratio after treatment had a tendency to be similar to that in HVs (before, 0.51 ± 0.66; after, 0.32 ± 0.20; HVs, 0.20 ± 0.08; Fig. 5C, P = 0.06). Although there was no statistical difference in the ANA ratio before and after treatment, ANA imbalance may be attenuated by the treatment.

Figure 5.

figure

Effect of treatment of vertigo on autonomic nervous activity.

Sympathetic nervous activity (A), parasympathetic nervous activity (B), and autonomic nervous activity ratio expressed as the sympathetic/parasympathetic nervous activity ratio in vertigo patients (n = 41) before (left) and after (right) treatment. Gray zone indicates the mean ± SD of healthy volunteers (n = 23). HF, high frequency; LF, low frequency; LN, logarithmus naturalis.

Discussion

In our study, we quantitatively evaluated physiological stress in vertigo patients by measuring OS and ANA. As an OS biomarker, dROM were significantly higher in vertigo patients than in HVs (Fig. 2B). Parasympathetic nervous activity, as quantified by HF of HRV, was significantly suppressed in vertigo patients compared with HVs (Fig. 3B).

Similar to our findings, some studies have reported an elevation of OS in vertigo patients.3, 4, 11 The production of dROM results from several mechanisms, including oxidative phosphorylation in the mitochondria as a product of normal cellular aerobic metabolism.12, 13 Thus, dROM can be produced by the major process from which the body derives energy.13 The balance between dROM production and activation of the antioxidant defense system is crucial in human physiology and the control of cellular homeostasis.14 Although dROM play an important role in signaling processes, their overproduction generates OS. Reactive oxygen metabolites can regulate cellular functions during immune and inflammatory processes,15 which cause the overproduction of OS. Therefore, it is difficult to determine the source of production of dROM. It is possible that OS promotes vasculitis of the vertebrae and endolymphatic hydrops in vertigo patients.3, 4 Measurement of OS could evaluate not only the severity of vertigo but also the cause of vertigo.

Previous studies7, 8, 11, 16 have reported significant parasympathetic nervous hypofunction in vertigo patients, which is similar to the findings of our study (Fig. 3B). It was considered that the suppression of parasympathetic activity and the relative hyperfunction of sympathetic activity in vertigo patients influenced the vertebrobasilar arterial system. These pathophysiological mechanisms may produce laterality of peripheral vestibular function, thus resulting in vertigo.9 Therefore, one possible mechanism of vertigo is change in blood flow and pressure in the vertebrobasilar artery and cochleovestibular organs.

Our research also evaluated the effect of the treatment of vertigo on biological stress. Conventionally, 8.4% sodium bicarbonate and ATP disodium hydrate have been used for the treatment of vertigo. It is believed that sodium bicarbonate improves vertigo by acting on the central and peripheral vestibular system and correcting acidosis,17 while ATP disodium hydrate improves vertigo by increasing cerebral blood flow and cerebrovascular extension.18 After treatment, dROM decreased significantly (Fig. 4B) and ANA balance was also attenuated (Fig. 5C). Possibly, adding antioxidants to our medication protocol would enhance the effect of the conventional treatment. Our management of these patients now includes bedside monitoring of HRV and measurement of oxidative activity, which is very useful and can be measured repeatedly.

Our study has some limitations. First, patients with arrhythmia were excluded because accurate HRV analysis could not be carried out in these patients. However, some patients complaining of vertigo have synchronizing paroxysmal arrhythmia. Second, the age and sex of HVs and vertigo patients were different. Vertigo patients were older and included a higher number of females. This background difference could have induced a bias. Further studies are necessary using age‐ and sex‐matched HVs.

Conclusion

We quantitatively evaluated physiological stress in vertigo patients using OS and HRV. We found that OS was significantly higher and parasympathetic activity was significantly suppressed in vertigo patients. After conventional treatment of vertigo, dROM was reduced and ANA balance was improved. Bedside monitoring of OS and HRV may be useful for the diagnosis of vertigo and evaluation of the effect of treatment.

Conflict of Interest

None.

References

  • 1. Newman‐Toker DE, Hsieh YH, Camargo CA Jr, Pelletier AJ, Butchy GT, Edlow JA. Spectrum of dizziness visits to US emergency departments: Cross‐sectional analysis from a nationally representative sample. Mayo Clin. Proc. 2008; 83: 765–775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. House JW, Crary WG, Wexler M. The inter‐relationship of vertigo and stress. Otolaryngol. Clin. North Am. 1980; 13: 625–629. [PubMed] [Google Scholar]
  • 3. Calabrese V, Cornelius C, Maiolino L et al Oxidative stress, redox homeostasis and cellular stress response in Ménière's disease: Role of vitagenes. Neurochem. Res. 2010; 35: 2208–2217. [DOI] [PubMed] [Google Scholar]
  • 4. Raponi G, Alpini D, Volontè S, Capobianco S, Cesarani A. The role of free radicals and plasmatic antioxidant in Ménière's syndrome. Int. Tinnitus J. 2003; 9: 104–108. [PubMed] [Google Scholar]
  • 5. Takumida M, Anniko M, Ohtani M. Radical scavengers for Ménière's disease after failure of conventional therapy: A pilot study. Acta Otolaryngol 2003; 123: 697–703. [DOI] [PubMed] [Google Scholar]
  • 6. Akselrod S, Gordon D, Madwed JB, Snidman NC, Shannon DC, Cohen RJ. Hemodynamic regulation: Investigation by spectral analysis. Am. J. Physiol. 1985; 249: 867–875. [DOI] [PubMed] [Google Scholar]
  • 7. Kawasaki Y. Autonomic nervous function of vertiginous patients—assessment by spectral analysis of heart rate variability. Nippon Jibiinkoka Gakkai Kaiho 1993; 96: 444–456. (In Japanese.) [DOI] [PubMed] [Google Scholar]
  • 8. Yamada M, Mizuta K, Ito Y et al Autonomic nervous function in patients with Meniere's disease evaluated by power spectral analysis of heart rate variability. Auris Nasus Larynx 1999; 26: 419–426. [DOI] [PubMed] [Google Scholar]
  • 9. Takeda N. Autonomic dysfunction in patients with vertigo. Japan. Med. Assoc. J. 2006; 49: 153–157. [Google Scholar]
  • 10. Tanosoto T, Arima T, Tomonaga A, Ohata N, Svensson P. A paced auditory serial addition task evokes stress and differential effects on masseter‐muscle activity and haemodynamics. Eur. J. Oral Sci. 2011; 120: 363–367. [DOI] [PubMed] [Google Scholar]
  • 11. Goto F, Hayashi K, Kunihiro T, Ogawa K. The possible contribution of angiitis to the onset of benign paroxysmal positional vertigo (BPPV). Int. Tinnitus J. 2010; 16: 25–28. [PubMed] [Google Scholar]
  • 12. Davies KJ. Oxidative stress: The paradox of aerobic life. Biochem. Soc. Symp. 1995; 61: 1–31. [DOI] [PubMed] [Google Scholar]
  • 13. Ide T, Tsutsui H, Kinugawa S et al Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ. Res. 1999; 85: 357–363. [DOI] [PubMed] [Google Scholar]
  • 14. Corbi G, Conti V, Russomanno G et al Adrenergic signaling and oxidative stress: A role for sirtuins? Front. Physiol. 2013; 4: 324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Remacle J, Raes M, Toussaint O, Renard P, Rao G. Low levels of reactive oxygen species as modulators of cell function. Mutat. Res. 1995; 316: 103–122. [DOI] [PubMed] [Google Scholar]
  • 16. Goto F, Mizutari K, Kunihiro T, Ogawa K. Autonomic dysfunction in dizzy patients revealed by pulse analysis. Equilibrium Res. 2010; 69: 207–212. [Google Scholar]
  • 17. Kawabata A, Sasa M, Takaori S et al Inhibition by intravenously administrated sodium bicarbonate of neural activity in medial vestibular nucleus neurons. Jpn J. Pharmacol. 1990; 54: 383–389. [DOI] [PubMed] [Google Scholar]
  • 18. Forrester T, Harper AM, MacKenzie ET, Thomson EM. Effect of adenosine triphosphate and some derivatives on cerebral blood flow and metabolism. J. Physiol. 1979; 296: 343–355. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Acute Medicine & Surgery are provided here courtesy of Wiley

RESOURCES